Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
USA
Regulatory Approval:
N/A
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Talzenna (talazoparib) is a PARP inhibitor approved for two indications: as a single agent for adult patients with germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer, and in combination with enzalutamide for adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer.
Talzenna inhibits PARP enzymes, which are involved in repairing damaged DNA in cells. In cancer cells with BRCA or other HRR gene mutations that already impair DNA repair, blocking PARP leads to accumulated DNA damage and cancer cell death, a mechanism known as synthetic lethality.
Talzenna is used in breast cancer patients confirmed to carry a germline BRCA mutation, and in prostate cancer patients with HRR gene mutations, both requiring genetic testing to confirm eligibility.
For breast cancer monotherapy, the recommended dose is 1 mg orally once daily. For metastatic castration-resistant prostate cancer in combination with enzalutamide, the dose is 0.5 mg orally once daily.
Talzenna does not carry a formal FDA boxed warning. However, patients and prescribers should be aware of the following important safety information.
Cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) have been reported. Complete blood counts should be monitored throughout treatment, and Talzenna should be discontinued if MDS/AML is confirmed.
Anemia, neutropenia, and thrombocytopenia are common and may require dose interruption, reduction, or blood count monitoring throughout treatment.
Talzenna may cause fetal harm. Effective contraception should be used during treatment and for a period after the final dose, as advised by the treating physician.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Talzenna is manufactured and marketed by Pfizer. It is sourced through authorized distribution channels for patients seeking named-patient import into India.
Patients typically need a valid prescription from a treating oncologist confirming diagnosis and BRCA or HRR gene mutation testing results. NPP's regulatory team assists in preparing and verifying the documentation needed for a compliant import.
As an FDA-approved PARP inhibitor for BRCA-mutated breast cancer and HRR-mutated prostate cancer, Talzenna is sourced through authorized channels and imported under GDP-compliant logistics to preserve product quality throughout transit.
NPP sources Talzenna directly from authorized pharmaceutical distributors to ensure product authenticity and full traceability. Every shipment is handled under Good Distribution Practice (GDP) conditions from origin to the patient's doorstep.
Talzenna should be stored at 20°C to 25°C, with excursions permitted between 15°C and 30°C, and this condition is maintained throughout transit.
Once documentation and regulatory approvals are in place, delivery timelines are communicated transparently at the time of quotation, accounting for import clearance and last-mile logistics to the patient's city.
Patients across India can access Talzenna through NPP's regulated import pathway, with oncology specialists in major cities supporting the treatment process.
Leading hospitals in Mumbai support oncology care coordination and documentation for Talzenna access.
Delhi's major hospitals assist patients with prescription support and documentation for Talzenna.
Bangalore's specialist network offers access coordination for eligible BRCA-mutated cancer patients seeking Talzenna.
Chennai-based oncology specialists coordinate Talzenna access alongside comprehensive cancer care.
Hyderabad's care institutions support patients pursuing Talzenna therapy.
Kolkata's specialist centers help coordinate documentation and treatment access for Talzenna.
Pune-based specialists assist with prescription support and Talzenna treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Talzenna.
Kochi's specialist units assist patients with the documentation needed for Talzenna access.
Chandigarh's care centers support Talzenna treatment coordination for patients from North India.
Jaipur's specialists help patients navigate the Talzenna access process.
Lucknow-based centers assist patients pursuing Talzenna therapy.
Bhubaneswar's institutions support access to Talzenna for eligible patients.
Guwahati's specialists help coordinate Talzenna access for patients across the Northeast.
Patients in other cities across India can also access Talzenna through NPP's nationwide coordination network.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 15 September 2026
Sources: FDA
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 15 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
